Literature DB >> 16555372

Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants.

Hani Tamim1, Jean-François Boivin, James Hanley, Maryrose Stang, Jean-Paul Collet.   

Abstract

PURPOSE: In 2002, we reported an epidemiological study in which we found that some tricyclic antidepressants (identified as genotoxic in Drosophila Melanogaster) were associated with an increased risk of breast cancer, when exposure took place 11-15 years before the date of diagnosis. The implications of the results found lead us to carry out a separate case-control study, using the same source population, to validate the conclusions drawn from our previous study.
METHODS: We accrued 7330 breast cancer cases, diagnosed between 1981 and 2000, and 29 320 controls matched on age and time.
RESULTS: The association between exposure to genotoxic TCAs 11-15 years before diagnosis and the risk of breast cancer development was much weaker, as compared to what was reported in our previous study. The relative risk of breast cancer in women exposed to high doses of genotoxic TCAs 11-15 years before diagnosis was 1.17 (95%CI: 0.79-1.74), while in women exposed to high levels of non-genotoxic TCAs during the same period it was 0.95 (95%CI: 0.61-1.48).
CONCLUSION: In conclusion, we did not find supporting evidence for an increased risk of breast cancer among women exposed to TCAs up to 20 years in the past. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555372     DOI: 10.1002/pds.1233

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  Depression, Antidepressant Use, and Postmenopausal Breast Cancer Risk.

Authors:  Susan B Brown; Susan E Hankinson; Kathleen F Arcaro; Jing Qian; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-17       Impact factor: 4.254

2.  Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer.

Authors:  Paul J Fitzgerald
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

Review 3.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

Review 4.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

5.  A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency.

Authors:  J E Ashbury; L E Lévesque; P A Beck; K J Aronson
Journal:  BMC Med       Date:  2010-12-22       Impact factor: 8.775

6.  Antidepressants in association with reducing risk of oral cancer occurrence: a nationwide population-based cohort and nested case-control studies.

Authors:  Chia-Min Chung; Tzer-Min Kuo; Shang-Lun Chiang; Zhi-Hong Wang; Chung-Chieh Hung; Hsien-Yuan Lane; Chiu-Shong Liu; Ying-Chin Ko
Journal:  Oncotarget       Date:  2016-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.